Scienture Holdings, Inc.
About Scienture Holdings, Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $431.6K
- Net income
- -$41.5M
- Total assets
- $84.2M
- Market cap
- $14.6M
- Gross margin
- 76.8%
- Operating margin
- -9867.9%
- Net margin
- -9618.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $431.6K
- Cost of revenue
- $100.1K
- Gross profit
- $331.5K
- Operating expenses
- $42.9M
- Operating income
- -$42.6M
- Income tax
- -$2.0M
- Net income
- -$41.5M
- EPS (basic)
- $-2.70
- EPS (diluted)
- $-2.70
Balance sheet
- Total assets
- $84.2M
- Current assets
- $7.9M
- Total liabilities
- $14.1M
- Current liabilities
- $2.7M
- Shareholders’ equity
- $70.1M
Cash flow
- Operating cash flow
- -$13.4M
- Investing cash flow
- -$6.4M
- Financing cash flow
- $19.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $14.6M
- EPS (diluted)
- $-2.7
- Shares outstanding
- 41.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 22, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $41.5M in FY2025.
- Revenue grew 216% from FY2024 to FY2025.
- Gross margin of 76.8%, net margin -9618.0%.
- Trading 87% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Scienture Holdings, Inc..
Write a review
News about Scienture Holdings, Inc.
News & sentiment via Polygon.io
